245 related articles for article (PubMed ID: 9506550)
1. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.
Molyneux PD; Filippi M; Barkhof F; Gasperini C; Yousry TA; Truyen L; Lai HM; Rocca MA; Moseley IF; Miller DH
Ann Neurol; 1998 Mar; 43(3):332-9. PubMed ID: 9506550
[TBL] [Abstract][Full Text] [Related]
2. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
[TBL] [Abstract][Full Text] [Related]
3. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
4. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
Barkhof F; van Walderveen M
Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1675-86. PubMed ID: 10603619
[TBL] [Abstract][Full Text] [Related]
5. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
6. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
Smith ME; Stone LA; Albert PS; Frank JA; Martin R; Armstrong M; Maloni H; McFarlin DE; McFarland HF
Ann Neurol; 1993 May; 33(5):480-9. PubMed ID: 8498825
[TBL] [Abstract][Full Text] [Related]
7. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
[TBL] [Abstract][Full Text] [Related]
8. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
9. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
10. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
11. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.
Moraal B; van den Elskamp IJ; Knol DL; Uitdehaag BM; Geurts JJ; Vrenken H; Pouwels PJ; van Schijndel RA; Meier DS; Guttmann CR; Barkhof F
Ann Neurol; 2010 May; 67(5):667-75. PubMed ID: 20437564
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J
Ann Neurol; 1996 Jan; 39(1):6-16. PubMed ID: 8572668
[TBL] [Abstract][Full Text] [Related]
13. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.
McFarland HF; Frank JA; Albert PS; Smith ME; Martin R; Harris JO; Patronas N; Maloni H; McFarlin DE
Ann Neurol; 1992 Dec; 32(6):758-66. PubMed ID: 1471866
[TBL] [Abstract][Full Text] [Related]
14. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.
Tortorella C; Bellacosa A; Paolicelli D; Fuiani A; Di Monte E; Simone IL; Giaquinto P; Livrea P; Trojano M
J Neurol Sci; 2005 Dec; 239(1):95-9. PubMed ID: 16209877
[TBL] [Abstract][Full Text] [Related]
15. [Magnetic resonance imaging in multiple sclerosis].
Tourbah A; Berry I
Pathol Biol (Paris); 2000 Mar; 48(2):151-61. PubMed ID: 10815291
[TBL] [Abstract][Full Text] [Related]
16. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.
Massacesi L; Parigi A; Barilaro A; Repice AM; Pellicanò G; Konze A; Siracusa G; Taiuti R; Amaducci L
Arch Neurol; 2005 Dec; 62(12):1843-7. PubMed ID: 16344342
[TBL] [Abstract][Full Text] [Related]
18. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
19. Correlations between magnetization transfer metrics and other magnetic resonance abnormalities in multiple sclerosis.
Rovaris M; Horsfield MA; Filippi M
Neurology; 1999; 53(5 Suppl 3):S40-5. PubMed ID: 10496210
[TBL] [Abstract][Full Text] [Related]
20. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
